AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie has announced a USD 195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic ...

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...

AbbVie announced a significant expansion at its North Chicago facility, with plans to enhance U.S. production capacities for ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories spinoff AbbVie will ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...